FUJIKAWA Keita | Product Development Division, Bayer Yakuhin, Ltd.
スポンサーリンク
概要
関連著者
-
FUJIKAWA Keita
Product Development Division, Bayer Yakuhin, Ltd.
-
Fujikawa Keita
Product Development Division Bayer Yakuhin Ltd
-
Hasebe Naoyuki
First Department of Internal Medicine, Asahikawa Medical College
-
Kikuchi Kenjiro
First Department of Internal Medicine, Asahikawa Medical College
-
Hasebe Naoyuki
First Department Of Internal Medicine Asahikawa Medical College
-
Saito Ikuo
Health Center School Of Medicine Keio University
-
Kikuchi Kenjiro
First Department Of Internal Medicine Asahikawa Medical College
-
Saruta Takao
Internal Medicine School Of Medicine Keio University
-
Saruta Takao
Internal Medicine Keio University School Of Medicine
-
OTANI TOSHIKAZU
Department of Urology, Chubu Rosai Hospital
-
Nice-combi Study
Refer To The Appendix
-
Fujikawa Keita
Product Development Division Bayer Yakuhin Ltd.
-
KIMOTO Yasusuke
Department of Urology, Spinal Injuries Center
-
Saito Ikuo
Health Center Keio University
-
Yamamoto Noriyuki
Product Development Division Bayer Yakuhin Ltd
-
SAKAMOTO SADAAKI
Department of Urology, Nakamura Hospital
-
TACHIBANA TAKASHI
Product Development Division, Bayer Yakuhin Ltd
-
Kimoto Yasusuke
Department Of Urology Spinal Injuries Center
-
Kimoto Yasusuke
Department Of Urology Faculty Of Medicine Kyushu University
-
Otani Toshikazu
Department Of Urology Chubu Rosai Hospital
-
Otani Toshikazu
Department Of Urology Chubu-rosai Hospital
-
Sakamoto Sadaaki
Department Of Urology Nakamura Hospital
-
Tachibana Takashi
Product Development Division Bayer Yakuhin Ltd
著作論文
- Cost-Effectiveness Analysis of Hypertension Treatment : Controlled Release Nifedipine and Candesartan Low-Dose Combination Therapy in Patients with Essential Hypertension : The Nifedipine and Candesartan Combination (NICE-Combi) Study
- Up-titration of vardenafil dose from 10mg to 20mg improved erectile function in men with spinal cord injury
- Cost-Effectiveness Analysis : Controlled-Release Nifedipine and Valsartan Combination Therapy in Patients with Essential Hypertension : The Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) Study